This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Nevro (NVRO) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Nevro (NVRO) delivered earnings and revenue surprises of 31.37% and 3.56%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
AxoGen (AXGN) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
AxoGen (AXGN) delivered earnings and revenue surprises of 40% and 1.60%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Wall Street Analysts Predict a 1249.93% Upside in Helius Medical Technologies, Inc. (HSDT): Here's What You Should Know
by Zacks Equity Research
The mean of analysts' price targets for Helius Medical Technologies, Inc. (HSDT) points to a 1249.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
How Much Upside is Left in Helius Medical Technologies, Inc. (HSDT)? Wall Street Analysts Think 1183.3%
by Zacks Equity Research
The consensus price target hints at an 1183.3% upside potential for Helius Medical Technologies, Inc. (HSDT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Helius Medical Technologies, Inc. (HSDT) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Helius Medical Technologies, Inc. (HSDT) delivered earnings and revenue surprises of 45.45% and 50.59%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Pfizer (PFE) Surpasses Q2 Earnings Estimates
by Zacks Equity Research
Pfizer (PFE) delivered earnings and revenue surprises of 19.64% and 2.03%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Edwards Lifesciences (EW) Surpasses Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Edwards Lifesciences (EW) delivered earnings and revenue surprises of 1.54% and 1.65%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Silk Road Medical (SILK) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Silk Road Medical (SILK) delivered earnings and revenue surprises of -10.26% and 1.68%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Inogen (INGN) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Inogen (INGN) delivered earnings and revenue surprises of 18.18% and 2.80%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
5 Winning Stocks Backed by the Overlooked Rising P/E Trick
by Sanghamitra Saha
Want to try an out-of-the-box approach? Tap AMC Entertainment (AMC), Live Nation Entertainment (LYV), CuriosityStream (CURI), Helius Medical Technologies (HSDT) and Vir Biotechnology (VIR).
Helius Medical Technologies, Inc. (HSDT) Moves to Buy: Rationale Behind the Upgrade
by Zacks Equity Research
Helius Medical Technologies, Inc. (HSDT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Stereotaxis Inc. (STXS) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Stereotaxis Inc. (STXS) delivered earnings and revenue surprises of -16.67% and 2.46%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Masimo (MASI) Q3 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Masimo (MASI) delivered earnings and revenue surprises of 8.70% and 2.87%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
What Makes Helius Medical Technologies, Inc. (HSDT) a New Buy Stock
by Zacks Equity Research
Helius Medical Technologies, Inc. (HSDT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Helius Medical Technologies, Inc. (HSDT) Upgraded to Buy: Here's Why
by Zacks Equity Research
Helius Medical Technologies, Inc. (HSDT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Helius Medical Technologies, Inc. (HSDT) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Helius Medical Technologies, Inc. (HSDT) delivered earnings and revenue surprises of -14.86% and 37.98%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Helius Medical Technologies, Inc. (HSDT) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
Helius Medical Technologies, Inc. (HSDT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
New Strong Sell Stocks for August 20th
by Zacks Equity Research
ADXN, CSSE, HSDT, LYRA, and TRVN have been added to the Zacks Rank #5 (Strong Sell) List on August 20, 2021.
Helius Medical Technologies, Inc. (HSDT) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Helius Medical Technologies, Inc. (HSDT) delivered earnings and revenue surprises of -68.63% and -21.11%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Will Helius Medical Technologies, Inc. (HSDT) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
Helius Medical Technologies, Inc. (HSDT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Helius Medical Technologies, Inc. (HSDT) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Helius Medical Technologies, Inc. (HSDT) delivered earnings and revenue surprises of 33.33% and 33.00%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Helius Medical Technologies, Inc. (HSDT) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
by Zacks Equity Research
Helius Medical Technologies, Inc. (HSDT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Helius Medical Technologies, Inc. (HSDT) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Helius Medical Technologies, Inc. (HSDT) delivered earnings and revenue surprises of 0.00% and -50.00%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?